Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
about
Extensive Central Nervous System Cryptococcal Disease Presenting as Immune Reconstitution Syndrome in a Patient with Advanced HIV: Report of a Case and Review of Management Dilemmas and StrategiesModelling imperfect adherence to HIV induction therapyMechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic ControllersTreatment interruption and variation in tablet taking behaviour result in viral failure: a case-control study from Cape Town, South Africa.Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factorsCorrelates of unstructured antiretroviral treatment interruption in a cohort of HIV-positive individuals in British Columbia.Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in CanadaCritical illness in HIV-infected patients in the era of combination antiretroviral therapy.Commentary: Questioning the HIV-AIDS Hypothesis: 30 Years of DissentSelf-initiation of antiretroviral therapy in the developing world: the involvement of private pharmacies in an HIV program.Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010.Effects of unplanned treatment interruptions on HIV treatment failure - results from TAHODOutcomes of Nigeria's HIV/AIDS Treatment Program for Patients Initiated on Antiretroviral Treatment between 2004-2012.The interferon-induced antiviral protein PML (TRIM19) promotes the restriction and transcriptional silencing of lentiviruses in a context-specific, isoform-specific fashion.Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trialRisk factors for unstructured treatment interruptions and association with survival in low to middle income countriesEffects of political conflict-induced treatment interruptions on HIV drug resistanceAntiretroviral treatment interruptions induced by the Kenyan postelection crisis are associated with virological failure.Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract.Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review.Urological aspects of HIV and AIDS.Proposal of Standardization to Assess Adherence With Medication Records: Methodology Matters.HIV and Stem Cell Transplantation.Socioeconomic and clinical factors explaining the risk of unstructured antiretroviral therapy interruptions among Kenyan adult patients.Low Non-structured Antiretroviral Therapy Interruptions in HIV-Infected Persons Who Inject Drugs Receiving Multidisciplinary Comprehensive HIV Care at an Outpatient Drug Abuse Treatment Center.Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.Evaluating a multi-component, community-based program to improve adherence and retention in care among adolescents living with HIV in Zimbabwe: study protocol for a cluster randomized controlled trial.US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.Characterizing Human Immunodeficiency Virus Antiretroviral Therapy Interruption and Resulting Disease Progression Using Population-Level Data in British Columbia, 1996-2015.Associations Between Medicare Part D and Out-of-Pocket Spending, HIV Viral Load, Adherence, and ADAP Use in Dual Eligibles With HIV.Which strings attached: ethical considerations for selecting appropriate conditionalities in conditional cash transfer programmes.
P2860
Q26852378-DBE0B073-462A-4E8D-92DC-8B6C0B20F54CQ33523201-2795C728-3625-4238-AAA9-34B0D269E8EAQ33828507-4DF827B9-EE35-4F78-8C1B-CCDF2221831BQ33999150-7A474545-F8BD-4A09-98DF-DE7DDDD4D639Q34508220-E0C708BD-0F2F-40F2-B478-5AE3742837F8Q34756298-0DF1A865-73E8-43C0-9053-FEDDB855F52FQ34989696-18F508D5-CE61-41C3-A51D-B8350C6FB32DQ35095045-160E4E35-4018-42D9-A583-AEB2D1276339Q35925705-3D4DB57B-64D6-4BEB-B746-812D654BD36EQ35938895-FB055180-7C0E-4E6C-BA53-57B99B147B06Q35944787-884640CC-4EDE-47DE-8144-C36CF4D49052Q35948083-75DD651E-4E57-4A7A-9DD0-26319728C9FCQ36187496-63255BA3-B674-4F18-BE40-89A94B90858EQ36714770-BE3A1376-CA25-4829-A585-BEF0B47CB5CDQ36859148-91C555BB-29F1-4737-AF46-AB4682BA23F4Q36882476-63EFC4D0-AE2E-4164-9A35-7807447CCF8FQ37085020-AB8D435B-0993-4554-886D-931FC70F807DQ37175897-D45E26F4-ECAE-4107-87A4-75211B3023ECQ37577550-5AF492EC-A409-41CC-B217-D6DFB2957E8CQ37643618-3F1F72C1-E961-422C-9D52-BA6CD5C1FBB2Q37896165-34AAF9B2-143A-410C-AEEA-E481EDF677FAQ38156073-F6E55426-D94D-42D4-8693-42B2737E02FAQ38903094-FDF92795-5B9F-46B2-8ADE-A4D40359D737Q39145369-4612721C-AD0B-4020-994E-AC62816A7A74Q40023160-11D4250D-7E18-43A7-9EA8-A90D63473E00Q40477509-2CC7FFDD-42CC-4313-A7D9-EE0B865928E9Q42256493-24D85B8A-99B5-4087-A2C4-B1E5DDEA43A9Q42668987-F937C61B-F57A-485C-8611-B259E34019E2Q42772433-B9ACF558-BD46-4113-B96F-A705A2828735Q45326055-E20E7A19-7276-47C5-87B8-F9FC60A077ADQ46900189-A1DF5797-064C-4A72-A3FB-3766C6BCD887Q47138169-DECBE110-6D54-49AF-A193-1EDD00A01D2B
P2860
Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Interruption of combination an ...... progression to AIDS or death.
@en
Interruption of combination an ...... progression to AIDS or death.
@nl
type
label
Interruption of combination an ...... progression to AIDS or death.
@en
Interruption of combination an ...... progression to AIDS or death.
@nl
prefLabel
Interruption of combination an ...... progression to AIDS or death.
@en
Interruption of combination an ...... progression to AIDS or death.
@nl
P2093
P2860
P1433
P1476
Interruption of combination an ...... progression to AIDS or death.
@en
P2093
A Blaxhult
A N Phillips
C Holkmann Olsen
EuroSIDA study group
J D Lundgren
P2860
P304
P356
10.1111/J.1468-1293.2007.00436.X
P577
2007-03-01T00:00:00Z